These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18610555)

  • 1. Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.
    Bassit L; Grier J; Bennett M; Schinazi RF
    Antivir Chem Chemother; 2008; 19(1):25-31. PubMed ID: 18610555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.
    Panigrahi R; Hazari S; Chandra S; Chandra PK; Datta S; Kurt R; Cameron CE; Huang Z; Zhang H; Garry RF; Balart LA; Dash S
    PLoS One; 2013; 8(8):e72791. PubMed ID: 24009705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
    Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
    J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA.
    Kanda T; Yokosuka O; Imazeki F; Tanaka M; Shino Y; Shimada H; Tomonaga T; Nomura F; Nagao K; Ochiai T; Saisho H
    J Viral Hepat; 2004 Nov; 11(6):479-87. PubMed ID: 15500548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
    Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
    J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.
    Kato T; Date T; Miyamoto M; Sugiyama M; Tanaka Y; Orito E; Ohno T; Sugihara K; Hasegawa I; Fujiwara K; Ito K; Ozasa A; Mizokami M; Wakita T
    J Clin Microbiol; 2005 Nov; 43(11):5679-84. PubMed ID: 16272504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.
    Ma H; Le Pogam S; Fletcher S; Hinojosa-Kirschenbaum F; Javanbakht H; Yan JM; Jiang WR; Inocencio N; Klumpp K; Nájera I
    Antimicrob Agents Chemother; 2014 May; 58(5):2614-25. PubMed ID: 24550342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of subgenomic hepatitis C virus RNA replication in HeLa cells.
    Kanda T; Yokosuka O; Mikata R; Zhang KY; Tanaka M; Tada M; Fukai K; Imazeki F; Saisho H
    Hepatogastroenterology; 2007; 54(73):32-5. PubMed ID: 17419226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
    Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
    Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity of nucleoside analogues against norovirus.
    Costantini VP; Whitaker T; Barclay L; Lee D; McBrayer TR; Schinazi RF; Vinjé J
    Antivir Ther; 2012; 17(6):981-91. PubMed ID: 22910194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.
    Escuret V; Martin A; Durantel D; Parent R; Hantz O; Trépo C; Menguy T; Bottius E; Dardy J; Maral J; Escary JL; Zoulim F
    Antimicrob Agents Chemother; 2006 Dec; 50(12):3984-91. PubMed ID: 17030563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance.
    Vliegen I; Paeshuyse J; Zhong W; Neyts J
    Antiviral Res; 2015 Aug; 120():112-21. PubMed ID: 26036224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
    Marcellin P; Horsmans Y; Nevens F; Grange JD; Bronowicki JP; Vetter D; Purdy S; Garg V; Bengtsson L; McNair L; Alam J
    J Hepatol; 2007 Oct; 47(4):476-83. PubMed ID: 17629590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway.
    Frese M; Pietschmann T; Moradpour D; Haller O; Bartenschlager R
    J Gen Virol; 2001 Apr; 82(Pt 4):723-733. PubMed ID: 11257176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine.
    Lam AM; Espiritu C; Murakami E; Zennou V; Bansal S; Micolochick Steuer HM; Niu C; Keilman M; Bao H; Bourne N; Veselenak RL; Reddy PG; Chang W; Du J; Nagarathnam D; Sofia MJ; Otto MJ; Furman PA
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2566-75. PubMed ID: 21444700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway.
    Liu WL; Yang HC; Su WC; Wang CC; Chen HL; Wang HY; Huang WH; Chen DS; Lai MY
    PLoS One; 2012; 7(9):e43824. PubMed ID: 22962590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.